Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Approval decisionStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| MOLBREEVI (Molgramostim) | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | PDUFA | Nov 22, 2026 | Big moverMgmt interestHedge fund pick |
Upcoming milestones
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Approval decisionCompany profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.